Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • dose reduction
Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission
Posted inClinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

Posted by MedXY By MedXY 10/01/2025
A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.
Read More
Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?
Posted inClinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

Posted by MedXY By MedXY 09/25/2025
Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.
Read More
Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial
Posted inClinical Updates news Oncology Radiology Specialties

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

Posted by MedXY By MedXY 08/07/2025
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.
Read More
  • ICSI vs. Conventional IVF: New Evidence Suggests No Kinetic Advantage and Lower High-Quality Blastocyst Yield in Non-Male Factor Infertility
  • Frozen Embryo Transfer and Offspring Development: Higher Birthweight Drives Increased Bone Mineralization While BMI Remains Stable
  • AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases
  • Beyond the Lead Apron: New Evidence of High Orthopedic and Reproductive Risks in Cardiac Electrophysiology
  • Cervical Stromal Involvement and Morphology Redefine LG-ESS Prognosis: Why Radiotherapy May Not Be the Answer
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in